Analysts Offer Insights on Healthcare Companies: Clovis Oncology (NASDAQ: CLVS) and Unum Therapeutics Inc (NASDAQ: UMRX)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clovis Oncology (CLVSResearch Report) and Unum Therapeutics Inc (UMRXResearch Report) with bullish sentiments.

Clovis Oncology (CLVS)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Clovis Oncology, with a price target of $36. The company’s shares closed yesterday at $14.43, close to its 52-week low of $11.50.

White noted:

“Our $36 price target is derived from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rubraca in ovarian cancer combination and prostate cancer indications, and the net present value (NPV) for the current commercial business.”

According to TipRanks.com, White is a 5-star analyst with an average return of 20.4% and a 52.0% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Aeglea Biotherapeutics Inc, and Spectrum Pharmaceuticals.

Currently, the analyst consensus on Clovis Oncology is a Moderate Buy with an average price target of $26.43.

See today’s analyst top recommended stocks >>

Unum Therapeutics Inc (UMRX)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Unum Therapeutics Inc, with a price target of $18. The company’s shares closed yesterday at $2.19, close to its 52-week low of $2.10.

Fein wrote:

“Our price target of $18/share is based on an equally-weighted composite of: (a) $18.2/share, as a 25x multiple of taxed and diluted $7.75 discounted back to FY19 at 30% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $17.3/ share (discounted cash flow analysis using a 18% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company).”

According to TipRanks.com, Fein is a 2-star analyst with an average return of 0.5% and a 41.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.

Unum Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $18, a 721.9% upside from current levels. In a report released today, Morgan Stanley also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.